Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in number of participants experiencing one or more episode requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing one or more episodes requiring ED visit · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episodes requiring hospital admission · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Total number of withdrawals · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in withdrawals ‐ Total number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing one or more episode requiring treatment with oral steroids · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episode requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episodes requiring ED visit · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episodes requiring hospital admission · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Total number of withdrawals · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in withdrawals ‐ Total number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review